Both EZH2 and EED degradation by EZH2–EED interactionimpairment (5b) or by EZH2–EED–PROTAC offera significant additional opportunity to block the PRC2 oncogenic activity,above all in the treatment of cancer types resistant to the EZH2 orthostericinhibitors. This evidence concerns the gene EZH2 and cancer.